The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation : Summary of the document prepared by the Czech Society of Cardiology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F18%3A00077230" target="_blank" >RIV/00023001:_____/18:00077230 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/18:73592003

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0010865018300535" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0010865018300535</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2018.05.001" target="_blank" >10.1016/j.crvasa.2018.05.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation : Summary of the document prepared by the Czech Society of Cardiology

Popis výsledku v původním jazyce

Non-vitamin K antagonist oral anticoagulants have an improved efficacy/safety ratio, a predictable anticoagulant effect without need for routine coagulation monitoring, and fewer food and drug interactions compared with VKAs. However, the proper use of NOACs requires a carefully considered approach to many practical aspects. Knowledge of kidney function is required, since all NOACs have precautions and contraindications based on creatinine clearance (CrCl). Also, product characteristics (as explained in the SmPCs), patient-related clinical factors, and patient preference need to be taken into account.

Název v anglickém jazyce

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation : Summary of the document prepared by the Czech Society of Cardiology

Popis výsledku anglicky

Non-vitamin K antagonist oral anticoagulants have an improved efficacy/safety ratio, a predictable anticoagulant effect without need for routine coagulation monitoring, and fewer food and drug interactions compared with VKAs. However, the proper use of NOACs requires a carefully considered approach to many practical aspects. Knowledge of kidney function is required, since all NOACs have precautions and contraindications based on creatinine clearance (CrCl). Also, product characteristics (as explained in the SmPCs), patient-related clinical factors, and patient preference need to be taken into account.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

26

Strana od-do

"E421"-"E446"

Kód UT WoS článku

000442902500014

EID výsledku v databázi Scopus

2-s2.0-85051662246